Literature DB >> 20011872

Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties.

Paulo Roberto Barbosa Evora1, Paulo José de Freitas Ribeiro, Walter Vilella de Andrade Vicente, Celso Luís dos Reis, Alfredo José Rodrigues, Antonio Carlos Menardi, Lafaiete Alves Junior, Patrícia Martinez Evora, Solange Bassetto.   

Abstract

OBJECTIVE: There is strong evidence that methylene blue (MB), an inhibitor of guanylate cyclase, is an excellent therapeutic option for vasoplegic syndrome (VS) treatment in heart surgery. The aim of this article is to review the MB's therapeutic function in the vasoplegic syndrome treatment.
METHODS: Fifteen years of literature review.
RESULTS: 1) Heparin and ACE inhibitors are risk factors; 2) In the recommended doses it is safe (the lethal dose is 40 mg/kg); 3) The use of MB does not cause endothelial dysfunction; 4) The MB effect appears in cases of nitric oxide (NO) up-regulation; 5) MB is not a vasoconstrictor, by blocking of the GMPc system it releases the AMPc system, facilitating the norepinephrine vasoconstrictor effect; 6) The most used dosage is 2 mg/kg as IV bolus followed by the same continuous infusion because plasmatic concentrations strongly decays in the first 40 minutes; 7) There is a possible 'window of opportunity' for the MB's effectiveness.
CONCLUSIONS: Although there are no definitive multicentric studies, the MB used to treat heart surgery VS, at the present time, is the best, safest and cheapest option, being a Brazilian contribution for the heart surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20011872     DOI: 10.1590/s0102-76382009000400005

Source DB:  PubMed          Journal:  Rev Bras Cir Cardiovasc


  23 in total

1.  Methylene blue does not have to be considered only as rescue therapy for distributive shock.

Authors:  Paulo Roberto Barbosa Evora
Journal:  J Med Toxicol       Date:  2013-12

2.  Methylene Blue Is a Guanylate Cyclase Inhibitor That Does Not Interfere with Nitric Oxide Synthesis.

Authors:  Paulo Roberto B Evora
Journal:  Tex Heart Inst J       Date:  2016-02-01

3.  Methylene blue modulates adhesion molecule expression on microvascular endothelial cells.

Authors:  Isabella Werner; Fengwei Guo; Ulrich A Stock; Michèle Lupinski; Patrick Meybohm; Anton Moritz; Andres Beiras-Fernandez
Journal:  Inflamm Res       Date:  2014-05-03       Impact factor: 4.575

4.  Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival.

Authors:  J Hunter Mehaffey; Lily E Johnston; Robert B Hawkins; Eric J Charles; Leora Yarboro; John A Kern; Gorav Ailawadi; Irving L Kron; Ravi K Ghanta
Journal:  Ann Thorac Surg       Date:  2017-05-24       Impact factor: 4.330

Review 5.  Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis.

Authors:  Jayme A Farina Junior; Andrea Carla Celotto; Marcelo Felix da Silva; Paulo Roberto B Evora
Journal:  Med Sci Monit       Date:  2012-05

Review 6.  Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised.

Authors:  Paulo Roberto Barbosa Evora; Lafaiete Alves Junior; Cesar Augusto Ferreira; Antônio Carlos Menardi; Solange Bassetto; Alfredo José Rodrigues; Adilson Scorzoni Filho; Walter Vilella de Andrade Vicente
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jan-Mar

7.  Effect of a single bolus of methylene blue prophylaxis on vasopressor and transfusion requirement in infective endocarditis patients undergoing cardiac surgery.

Authors:  Jin Sun Cho; Jong Wook Song; Sungwon Na; Joo-Hwa Moon; Young Lan Kwak
Journal:  Korean J Anesthesiol       Date:  2012-08-14

8.  Curbing inflammation in the ischemic heart disease.

Authors:  Paulo Roberto B Evora; Julio Nather; Paulo Victor Tubino; Agnes Afrodite S Albuquerque; Andrea Carla Celotto; Alfredo J Rodrigues
Journal:  Int J Inflam       Date:  2013-05-30

Review 9.  Pheochromocytoma resection: Current concepts in anesthetic management.

Authors:  Harish Ramakrishna
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Jul-Sep

10.  Methylene blue modulates transendothelial migration of peripheral blood cells.

Authors:  Isabella Werner; Fengwei Guo; Nicolai V Bogert; Ulrich A Stock; Patrick Meybohm; Anton Moritz; Andres Beiras-Fernandez
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.